| symbol |
CHMA |
|---|
| 会社名 | Chiasma Inc （キアズマ） |
|---|
| 分野（sector） |
Health Care
ヘルスケア
|
|---|
| 産業（industry） |
Major Pharmaceuticals
|
|---|
| 業種 |
医薬品
医療関連（Health Care）
|
|---|
| 概要 |
事業概要 Chiasma Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly a condition that results in the body's production of excess growth hormone. Octreotide is an analog of somatostatin a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation which is intended to be taken over twice a day. The Company's TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication. キアズマは米国のバイオ医薬品会社。臨床段階において、難病に対し従来の注射による治療法から経口型を開発、商業化することに従事する。独自技術(TPE)を用いて、患者の負担を軽減するために経口療法を開発する。過剰な成長ホルモンによる先端巨大症の治療薬として、経口オクトレオチドの臨床試験第3相を終了。マサチュ―セッツ州とイスラエルに本社を置く。 Chiasma is a commercial-stage biopharmaceutical company focused on developing and commercializing oral therapies to improve the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. In June 2020, Chiasma received FDA approval of MYCAPSSA for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA, the first and only oral somatostatin analog approved by the FDA, is available for commercial sale. Chiasma is headquartered in Needham, MA with a wholly owned subsidiary in Israel. MYCAPSSA, TPE and CHIASMA are registered trademarks of Chiasma.
|
|---|
| 本社所在地 | 460 Totten Pond Road Suite 530 Waltham MA 02451 USA |
|---|
| 代表者氏名 | David M. Stack David M. Stack |
|---|
| 代表者役職名 | Independent Chairman of the Board |
|---|
| 電話番号 | +1 617-928-5300 |
|---|
| 設立年月日 | 2001年 |
|---|
| 市場名 | NASDAQ National Market System |
|---|
| ipoyear | 2015年 |
|---|
| 従業員数 | 16人 |
|---|
| url | www.chiasmapharma.com |
|---|
| nasdaq_url | https://www.nasdaq.com/symbol/chma |
|---|
| adr_tso | ― |
|---|
| EBITDA | EBITDA（百万ドル） -29.16900 |
|---|
| 終値（lastsale） | 3.41 |
|---|
| 時価総額（marketcap） | 83157566.03 |
|---|
| 時価総額 | 時価総額（百万ドル） 90.96121 |
|---|
| 売上高 | 売上高（百万ドル） 0.00000 |
|---|
| 企業価値(EV) | 企業価値(EV)（百万ドル） 36.33621 |
|---|
| 当期純利益 | 当期純利益（百万ドル） -27.66800 |
|---|
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Chiasma Inc revenues was not reported. Net loss increased 13% to $15.7M. Higher net loss reflects Research and Development - other increase of 39% to $10.5M (expense) General and Administrative - other increase of 3% to $4.4M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.57 to -$0.64. |
|---|
CHMA - キアズマ （Chiasma Inc.） キアズマ